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Inorganic pyrophosphate can be accurately determined in 2 to 4 ml of serum or urine by an ion-exchange method. Pyrophosphate degradation by serum alkaline phosphatase and pyrophosphatase is stopped by adding to the serum 0.1 mmol of dithiothreitol (Cleland's reagent) per liter. This method is suitable for screening large numbers of patients. All of the patients studied who had classical symptoms of active osteogenesis imperfecta also had abnormally high concentrations of pyrophosphate in their serum. Of this group, 62% excreted increased amounts of pyrophosphates in their urine.
Seven adults with inactive osteogenesis imperfecta had 
Materials and Methods

Samples
Venous blood, 10 ml, was obtained from each of 34 controls and 28 patients with osteogenesis imperfecta. Most of these specimens were obtained in small hospitals where the patients had arranged to meet the investigators.
It is recommended but not essential that clotting and centrifugation be carried out at 4 #{176}C. The specimens were immediately centrifuged, and the serum was carefully separated from the clot and frozen at -20 #{176}C. Hemolyzed serum was discard- ed. Twenty-four-hour urine specimens, kept at 4 #{176}C during collection, were obtained from some of the patients, and one aliquot was kept frozen until analyzed. 
Inorganic Pyrophosphate
Results
Pyrophosphate
Analytical variables.
Recovery of pyrophosphate was consistently in the range of 95-105%. When 32P-labeled pyrophosphate was added to serum from controls and patients, the relative specific activity of the pyrophosphate peak did not differ significantly for the two groups. Charcoal added to the serum quantitatively removes nucleotides and does not affect the results (Table 1) 92-98% for PP1 plus serum. In another experiment, 32P-labeled sodium pyrophosphate was added to serum and allowed to stand for 0.5, 3.5, or 18 h at room temperature before chromatography; the percentages then analytically accounted for were 100%, 95%, and 86%, respectively.
If the serum was frozen within 3 h after collection, PP1 remained constant for several weeks, but samples that had been frozen for two to three months or longer had lost appreciable amounts of PP1. From these experiments we concluded that serum could safely be kept at room temperature (28 #{176}C) for 3 h, or in the frozen state for a few weeks. Day-to-day precision was 6% ± 1% (n = 100). With regard to the specificity of the assay, the specific activity of each fraction in the pyrophosphate peak did not differ significantly from unity over a wide range of concentration of PP1 and amounts of labeled PP1 used. Extraction of the serum phospholipids with a chloroform-nmethanol mixture did not alter the PP1 values arid addition of pure lecithin, sphingomyelin, or phosphatidylethanolamine likewise had no effect on PP1 recovery. Treatment with yeast pyrophosphatase (EC 3.6.1.1) completely removed the pyrophosphate peak. These findings concerning the validity of the analytical techniques used generally agree with the conclusions of others (12).
Results for normal persons and patients. Table 2 shows our results for serum analyses. The mean value of 50 ± 30 (2 SD) tg (n = 34) of pyrophosphate per deciliter of control serum is well separated from the mean of 134 tg/dl for serum from the subjects with active osteogenesis imperfecta.
Two separate groups of values for sera, without overlap, are thereby defined: controls, with a range of 20-80 of serum pyrophosphate per deciliter, and patients with osteogenesis imperfecta, for whom the range is 85-332 zg of pyrophosphate per deciliter. Patients with osteogenesis imperfecta differ statistically from the control population and are significant at the .0005 level by Student's t-test. Analysis of 502 sera collected from normal persons during several years by one of us (C. S.) resulted in a mean value of 63 ± 11 (2 SD) pg/dl. More recently, a separate group of 35 normal children and teenagers gave a mean value of 62 ± 11 (2 SD) zg/dl (13). Plasma PP1 values were also investigated and are much lower (11-34 zg/dl). Others reported plasma concentrations of 7-35 (9) and 11-32 ,zg/dl (10). Patients with active disease had three of these four clinical signs and all show elevated PP1 serum concentrations.
Clinical Signs as Related to Analytical Results
Some patients with nonactive disease had a variable pattern of clinical signs, although most had at least three of the four listed signs or symptoms, and all bad normal serum pyrophosphate concentrations.
Urinary Pyrophosphate Orthophosphate Ratio Figure 1 shows the relationship between urine pyro-and orthophosphate excretions for patients with active osteogenesis imperfecta.
Only eight of the 13 urines examined have an elevated ratio; in contrast, serum pyrophosphate is high in all 13 of the patients. Our normal PP1/P1 ratio is 1/280, near that (1/238) reported by others (7).
Effects of Treatment
Two patients who received some form of therapy are listed separately, in Table 3 . Patient A, whose serum inorganic pyrophosphate concentration was 47 tg/dl, had excessive sweating, laxity of joints, and blue sclera. She was receiving magnesium oxide therapy before the serum was assayed. Before she was started on this therapy, she had sustained a total of about 50 fractures and had undergone 10 rodding operations. At the time her serum was assayed in this study, she had sustained no additional fractures and had noticed a decrease in sweating since therapy began. Patient B had a pattern of clinical signs similar to that of patient A and had received calcitonin therapy for five months before the assay. His serum values for normal patients fall within the two lines; supranormal ratios are to the right of this area pyrophosphate of 47 g/dl was also within the normal range. Both of these patients had normal serum alkaline phosphatase (EC 3.1.3.1) activity.
Effect of Serum Alkaline Phosphatase Activity Table 4 presents data showing the significant effect of alkaline phosphatase activity on the concentration of inorganic pyrophosphate in serum. This well-described phenomenon (13) must be recognized and inhibited when serum PP, is being measured, especially in patients who have had recent fractures or who have elevated alkaline phosphatase because of their age. Patient No. 4 (Table 2) has clinically active osteogenesis imperfecta and is the father of two children with active disease. His first serum pyrophosphate measurement was 83 g/dl.
His alkaline phosphatase was elevated, 63 U/liter (upper limits of normal, 45 U/liter).
On a second occasion, the blood was separated into equal aliquots, allowed to clot in the cold, and centrifuged at 4 #{176}C. One specimen was processed in the usual manner and gave reproducible results for PP1 and alkaline phosphatase ( showed these clinical signs, but had normal serum pyrophosphate concentrations. Although the clinical signs are useful in diagnosis of osteogenesis imperfecta, they do not appear to us to reflect the degree of biochemical metabolic disturbance at a given time during the course of the disease, or to be specific for diagnosis. Even the most commonly used sign, blue sclera, was absent in two patients from the active and one from the nonactive group. Therefore, increased serum inorganic pyrophosphate concentrations seem to be a better indicator of disease activity in patients with osteogenesis imperfecta.
Because an appreciable portion of the serum pyrophosphate originates by release from platelets during clotting (2, 10), the possibility that serum provides information relating most directly to intracellular genetic disturbances is being studied.
